WASHINGTON, D.C., November 15, 2019 – Baker Botts L.L.P., a leading energy and technology law firm, today announced that its client Celgene Corporation obtained FTC approval of its transformative $74 billion merger with Bristol-Myers Squibb Company (“BMS”). As a condition of FTC approval, and to facilitate a timely closing of the merger, BMS and Celgene have agreed to divest Celgene’s Otezla OTEZLA® (apremilast) business to Amgen for a cash purchase price of $13.4 billion. The FTC’s press release announcing the agency’s decision can be found here.
The Baker Botts team was led by partner Stephen Weissman and associate Steve Pet. Both are located in the Washington, D.C. office. Mr. Weissman previously served as Deputy Director for the FTC’s Bureau of Competition (2013-2015).
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 725 lawyers practicing throughout a network of 14 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy and technology sectors. Throughout our 179-year history, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.